AN2 Therapeutics, Inc.
ANTX
$4.27
-$0.45-9.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.08% | -12.74% | 7.64% | 5.66% | -17.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.24% | -14.71% | -54.56% | -36.94% | -54.25% |
| Operating Income | -8.24% | 14.71% | 54.56% | 36.94% | 54.25% |
| Income Before Tax | -15.79% | 26.63% | 55.23% | 35.92% | 55.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.79% | 26.63% | 55.23% | 35.92% | 55.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.79% | 26.63% | 55.23% | 35.92% | 55.49% |
| EBIT | -8.24% | 14.71% | 54.56% | 36.94% | 54.25% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.98% | 27.69% | 55.74% | 36.54% | 55.71% |
| Normalized Basic EPS | -13.84% | 12.23% | 55.74% | 36.51% | 55.66% |
| EPS Diluted | -13.98% | 27.69% | 55.74% | 36.54% | 55.71% |
| Normalized Diluted EPS | -13.84% | 12.23% | 55.74% | 36.51% | 55.66% |
| Average Basic Shares Outstanding | 1.59% | 1.46% | 1.17% | 0.98% | 0.50% |
| Average Diluted Shares Outstanding | 1.59% | 1.46% | 1.17% | 0.98% | 0.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |